311.
Trends in the prevalence, awareness, treatment and control of hypertension: the
WHO MONICA Project / R. L.
[et al.] // Eur. J. Cardiovasc. Prev.
Rehabil. – 2006. – Vol. 13, № 1. – Р. 13-29.
312.
Tune J. D. Effects of leptin on cardiovascular physiology / J. D. Tune, R. V.
Considine // J. Am. Soc. Hypertens. – 2007. – Vol. 1, № 4. – P. 231-241.
313.
Vita J. A. Endothelial function a barometer for cardiovascular risk? / J. A. Vita,
J. F. Keaney // Circulation. – 2002. – Vol. 106. – P. 640-642.
314.
Von Willebrand factor and endothelial damage in essential hypertension / A.
D. Blann [et al.] // J. Hum. Hypertens. – 1993. – Vol. 7, № 2. – P. 107-111.
315.
von Willebrand factor and endothelial damage in essential hypertension / A. D.
Blann [et al.] // J. Hum. Hypertens. – 1993. – Vol. 7. – P. 107-111.
316.
Weidman P. Metabolic profile of indapamide sustained-release in patiens with
hypertension: data from three randomized double-blind studies / P. Weidman //
Drug Saf. – 2001. – Vol. 24, № 15. – P. 1155-1165.
317.
Weight reduction and pharmacologic treatment in obese hypertensives / K.
Masuo [et al.] // Am. J. Hypertens. – 2001. – Vol. 14. – P. 530-538.
318.
Weight, weight change, and coronary heart disease in women. Risk within the
normal weight range / W. C. Willet [et al.] // J. Am. Med. Assoc. – 1995. – Vol.
273. – P. 461-465.
319.
White coat hypertension: relevance to clinical and emergency medical services
personnel / T. V. Khan [et al.] // MedGenMed. – 2007. – Vol. 9, № 1. – P. 52.
320.
Wood D. Established
